Evommune, Inc.(EVMN)
$7.63-0.39 (-4.86%)
EVMN
Evommune, Inc. stock forecast
$7.63
At close:-0.39 (-4.86%)
Want to see EVMN full AI Analyst Report?
Evommune, Inc. (EVMN) Stock Forecast & Price Target
140 Followers
EVMN Analyst Ratings
Moderate Buy
8Buy3Hold0Sell
Based on 11 analysts giving stock ratings to Evommune, Inc. in the past 3 months
EVMN Stock 12 Month Forecast
Average Price Target
$22.00▲(188.34% Upside)Based on 11 Wall Street analysts offering 12 month price targets for Evommune, Inc. in the last 3 months. The average price target is $22.00 with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 188.34% change from the last price of $7.63.
Past 12 Months12 Month ForecastJan2026Oct2026
High$30.00
Average$22.00
Low$8.00
Highest Price TargetHighest$30.00Average Price Target$22.00Lowest Price TargetLowest$8.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | ― | hold | ― | Reiterated | 11/13/26 | ||
| Brian Abrahams | RBC Capital | $21 | buy | 175.23%Upside | Reiterated | 11/12/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | $30 | buy | 293.18%Upside | Reiterated | 11/05/26 | ||
| Alice Nettleton | UBS | $8 | hold | 4.85%Upside | Initiated | 10/11/26 | ||
| Prakhar Agrawal | Cantor Fitzgerald | ― | buy | ― | Reiterated | 09/17/26 | ||
| Thomas Smith | Leerink Partners | $28→$22 | buy | 188.34%Upside | Assigned | 09/10/26 | ||
| Matt Phipps | William Blair | ― | hold | ― | Reiterated | 09/09/26 | ||
| Kostas Biliouris | Oppenheimer | $26 | buy | 240.76%Upside | Reiterated | 09/09/26 | ||
| Martin Auster | Raymond James | $18 | buy | 135.91%Upside | Reiterated | 09/09/26 | ||
| Serge Belanger | Needham | $28 | buy | 266.97%Upside | Reiterated | 09/09/26 | ||
| Kaveri Pohlman | Clear Street | $28→$23 | buy | 201.44%Upside | Reiterated | 09/09/26 | ||
| Judah Frommer | Morgan Stanley | $26 | buy | 240.76%Upside | Assigned | 08/10/26 | ||
| Gavin Clark-Gartner | Evercore ISI | $22 | buy | 188.34%Upside | Reiterated | 08/10/26 | ||
| Andreas Argyrides | Chardan Capital | $42 | buy | 450.46%Upside | Initiated | 01/23/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Mitchell KapoorH.C. Wainwright | HoldReiterated | 11/13/26 | ― | ||
| Brian AbrahamsRBC Capital | BuyReiterated$21 | 11/12/26 | 175.23%Upside | ||
| Alex Thompson CFAStifel Nicolaus | BuyReiterated$30 | 11/05/26 | 293.18%Upside | ||
| Alice NettletonUBS | HoldInitiated$8 | 10/11/26 | 4.85%Upside | ||
| Prakhar AgrawalCantor Fitzgerald | BuyReiterated | 09/17/26 | ― | ||
| Thomas SmithLeerink Partners | BuyAssigned$28→$22 | 09/10/26 | 188.34%Upside | ||
| Matt PhippsWilliam Blair | HoldReiterated | 09/09/26 | ― | ||
| Kostas BiliourisOppenheimer | BuyReiterated$26 | 09/09/26 | 240.76%Upside | ||
| Martin AusterRaymond James | BuyReiterated$18 | 09/09/26 | 135.91%Upside | ||
| Serge BelangerNeedham | BuyReiterated$28 | 09/09/26 | 266.97%Upside | ||
| Kaveri PohlmanClear Street | BuyReiterated$28→$23 | 09/09/26 | 201.44%Upside | ||
| Judah FrommerMorgan Stanley | BuyAssigned$26 | 08/10/26 | 240.76%Upside | ||
| Gavin Clark-GartnerEvercore ISI | BuyReiterated$22 | 08/10/26 | 188.34%Upside | ||
| Andreas ArgyridesChardan Capital | BuyInitiated$42 | 01/23/26 | 450.46%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Evommune, Inc.
3 Months
Success Rate1/5 ratings generated profit
20%
Average Return
-27.98%
Copying Alex Thompson CFA's trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -27.98% per trade.
1 Year
Success Rate1/5 ratings generated profit
20%
Average Return
-29.18%
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -29.18% per trade.
2 Years
Success Rate1/5 ratings generated profit
20%
Average Return
-29.18%
Copying Alex Thompson CFA's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -29.18% per trade.
EVMN Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 12 | 11 | 14 | 12 | 9 |
| Buy | 3 | 1 | 1 | 1 | 1 |
| Hold | 2 | 5 | 5 | 8 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 17 | 17 | 20 | 21 | 17 |
In the current month, EVMN has received 10 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. EVMN average Analyst price target in the past 3 months is 22.00.
EVMN Financial Forecast
High$-0.66
Consensus$-0.99
Low$-1.25
EVMN Earnings Forecast
Next quarter’s earnings estimate for EVMN is -$0.99 with a range of -$1.25 to -$0.66. The previous quarter’s EPS was -$0.85. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
High$5M
Consensus$625K
Low$0.00
EVMN Sales Forecast
Next quarter’s sales forecast for EVMN is $625.00K with a range of $0 to $5.00M. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
EVMN Stock Forecast FAQ
What is EVMN’s average 12-month price target, according to analysts?
Based on analyst ratings, Evommune, Inc.’s 12-month average price target is $22.00.
What is EVMN’s upside potential, based on the analysts’ average price target?
Evommune, Inc. has 188.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EVMN a Buy, Sell or Hold?
Evommune, Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.
What is Evommune, Inc.’s price target?
The average price target for Evommune, Inc. is $22.00. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $30.00, the lowest forecast is $8.00. The average price target represents a 188.34% increase from the current price of $7.63.
What do analysts say about Evommune, Inc.?
Evommune, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of EVMN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
